Amneal Pharmaceuticals, Inc Class A Common Stock

Amneal Pharmaceuticals, Inc Class A Common Stock

Yahoo Finance • 23 days ago

1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds

1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn't mean it wil... Full story

Yahoo Finance • 27 days ago

3 Overrated Stocks We Think Twice About

3 Overrated Stocks We Think Twice About Great things are happening to the stocks in this article. They're all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, o... Full story

Yahoo Finance • 2 months ago

AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

AstraZeneca AZN and its partner Amgen AMGN jointly announced positive top-line data from the late-stage CROSSING study, which evaluated Tezspire (tezepelumab) in adults and adolescents with eosinophilic esophagitis (EoE). The study met all... Full story

Yahoo Finance • 2 months ago

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

The confidence level of Americans hit rock bottom in August. Growing concerns over sky-high inflation and the labor market outlook have been dampening their sentiment. Also, concerns have lately grown that oil prices could rise further and... Full story

Yahoo Finance • 2 months ago

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO RGNX stock plunged 24.9% on Monday after the FDA placed a clinical hold on its investigational one-time gene therapy, RGX-121, for the treatment of boys with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome.... Full story

Yahoo Finance • 2 months ago

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio ACET continues to make steady progress with prula-cel/prulacabtagene leucel (formerly known as ADI-001),the company's lead product candidate and primary clinical value driver in autoimmune diseases. It is a first-in-class invest... Full story

Yahoo Finance • 2 months ago

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

Acadia Pharmaceuticals ACAD announced that the European Commission (EC) has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and old... Full story

Yahoo Finance • 3 months ago

1 Russell 2000 Stock with Exciting Potential and 2 We Ignore

1 Russell 2000 Stock with Exciting Potential and 2 We Ignore The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies oft... Full story

Yahoo Finance • 3 months ago

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sec... Full story

Yahoo Finance • 3 months ago

Amneal (AMRX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Anthony DiMeoCo-Founder and Co-Chief Executive Officer - Chirag PatelCo-Founder and Co-Chief Executive Officer -... Full story

Yahoo Finance • 3 months ago

Amneal projects 2026 revenue of $3.1B-$3.2B while raising capex to about $150M

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q2 2026 MANAGEMENT VIEW * "Amneal is in the midst of the most transformative period in our company's history," said (Co-Founder, Co-CEO, President & Director Chirag Patel), adding t... Full story

Yahoo Finance • 4 months ago

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now positioned to address the majority of U.S. iohex... Full story

Yahoo Finance • 4 months ago

3 Reasons AMRX is Risky and 1 Stock to Buy Instead

3 Reasons AMRX is Risky and 1 Stock to Buy Instead Amneal currently trades at $16.70 and has been a dream stock for shareholders. It's returned 283% since July 2021, blowing past the S&P 500's 72.3% gain. The company has also beaten the i... Full story

Yahoo Finance • 4 months ago

Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing

[machine that makes capsules in a pharmaceutical laboratory - 3D rendering] Thibault Renard/iStock via Getty Images * Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) and Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/sy... Full story

Yahoo Finance • 5 months ago

How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amneal Pharmaceuticals is back in focus after analysts lifted their price target to US$16.00, alon... Full story

Yahoo Finance • 5 months ago

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Amneal Pharmaceuticals LLC Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Substantial increases in daily “G... Full story

Yahoo Finance • 5 months ago

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ:AMRX) and the best and worst performers in the generic pharmaceutic... Full story

Yahoo Finance • 6 months ago

2 Reasons AMRX is Risky and 1 Stock to Buy Instead

Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. Is there a buying opportunity in Amneal, or does it present a risk to your portfo... Full story

Yahoo Finance • 6 months ago

Amneal Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY26 outlook

* Amneal Pharmaceuticals press release [https://seekingalpha.com/pr/20506663-amneal-reports-first-quarter-2026-financial-results] (AMRX [https://seekingalpha.com/symbol/AMRX]): Q1 Non-GAAP EPS of $0.27 beats by $0.10. * Revenue of $722... Full story

Yahoo Finance • 6 months ago

Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amneal Pharmaceuticals (NasdaqGS:AMRX) has entered a definitive agreement to acquire Kashiv BioSci... Full story